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tests. CONCLUSIONS: The instrument constitutes a single tool to assess both patient 
and physician perceptions of psoriasis severity and treatment effect. The availability 
of a shared instrument may improve treatment decision-making, reconciliating patient 
and physician perceptions. An observational study with 100 dermatologists and 561 
patients is planned to assess agreement between patient and clinician perceptions; 
scoring and psychometric properties will also be validated.
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OBJECTIVES: This research has been driven by the need for a quality of life (QoL) 
instrument that speciﬁ cally assesses physical appearance. The BeautyQol instrument 
is a multi-dimensional, self administered questionnaire, which has been in develop-
ment for over three years in 16 languages. METHODS: In the item generation phase, 
semi directive interviews were conducted in 309 subjects. In the second phase an 
acceptability study was conducted on 874 subjects in France, UK, Germany, Spain, 
Sweden, Italy, Russia, USA, Brazil, Japan, India (Hindi and English) China and South 
Africa (Zulu, Sotho and English). In the third phase, a total of 3231 subjects were 
recruited. to complete the BeautyQoL questionnaire, a skin clinical checklist, SF-36 
and a socio-demographic questionnaire. a re-test has been carried out at 8 days on a 
subgroup of 652 subjects. The database was randomly divided into two subgroups 
and analyzed using a Rash analysis. Psychometric properties, construct validity, repro-
ducibility, internal and external consistency were tested. RESULTS: From the item 
generation phase, 62 questions were selected. General acceptability was very good in 
the 16 cultures, with a very low rate of no answers. The validation phase reduced the 
questionnaire in 44 questions structured in ﬁ ve dimensions explaining 76.7% of the 
total variance: Social Life, Self conﬁ dence, Psychological life, Vitality and Seduction. 
Internal consistency was high (Cronbach alpha coefﬁ cients between 0.932 and 0.978). 
Reproducibility at 8 days was satisfactory in all dimensions. External validity testing 
revealed that BeautyQol scores correlated signiﬁ cantly with all SF-36 scores except 
for Physical Function. Mean completion time was 7 minutes (median:5 minutes). 
CONCLUSIONS: These results demonstrate the validity and reliability of the Beau-
tyQol questionnaire as the very ﬁ rst international instrument speciﬁ c to physical 
appearance. It is expected that BeautyQoL will be an instrument that will measure 
QoL affected by cosmetic products, techniques and agents that alter physical 
appearance.
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OBJECTIVES: To investigate discrepancy in the perception of dermatologic diseases 
(DD) severity between patients and physicians. METHODS: A descriptive study was 
performed: 2459 patients with DD rated their level of disease severity on a ﬁ ve level 
scale: very mild, mild, moderate, severe, very severe (PtGA). Physician global assess-
ment (PhGA) was performed on the same scale. Fifty three physicians were involved 
in an out-patient setting for three weeks (March 2010) in a dermatologic research 
hospital, Rome, Italy. RESULTS: Patients were predominantly females (59%), with 
an high education and the majority were employed; mean age was 45.9 ± 18.5 for 
females and 44.5 ± 18 for males. No discrepancy between PhGA and PtGA was 
observed in 37% of cases; PtGA under-rated compared to the physician in 35%; and 
PtGA over-rated relative to the physicians in 28%. Statistically signiﬁ cant differences 
were observed between PtGA and PhGA in each of the ﬁ ve levels of judgement (P < 
0.001). Higher percentages of patients, in respect to physicians, reported very mild, 
severe and very severe evaluations. Physicians tended to overestimate for mild and 
moderate levels. Differences were observed between male and female physicians in the 
severity judgement, reaching a statistically signiﬁ cant difference for the very mild level 
(P < 0.001) where females were more represented. CONCLUSIONS: The perceived 
severity disease in DD was different between patients and physicians and it was dif-
ferent in patients in respect to sex. Only for very mild DD there was a difference in 
PhGA between males and females, with males underestimating the severity.
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OBJECTIVES: To review the available vision-related QoL instruments that could be 
used to investigate the consequences of refractive cataract surgery, in particular the 
beneﬁ t of spectacle independence. METHODS: A literature review was undertaken 
on PubMed and Embase databases using keywords “Refractive Surgical Procedures”, 
“Refractive Errors”, “Refractive”, “Questionnaire”, and “QoL”. Questionnaires were 
selected if they were developed for cataract or refractive surgery, based on the reading 
of the manuscript abstract. a further search was performed on PubMed, Embase and 
ProQolid databases to obtain information on development and psychometric valida-
tion of the questionnaires. Authors were contacted by email if missing data were 
identiﬁ ed from the published literature. Main characteristics of the questionnaires 
were described including number of items, targeted population, mode of administra-
tion, response scale, languages, and number of publications. Development methodol-
ogy was reviewed (literature review, clinician input, patient input and comprehension 
test). Psychometric properties were examined (e.g. domain description, scoring algo-
rithm, internal consistency, clinical validity, reproducibility, responsiveness). The 
above characteristics were then examined in light of the US FDA’s “Guidance for 
Industry Patient-Reported Outcome Measures: Use in Medical Product Development 
to Support Labeling Claims”. RESULTS: A total of 141 abstracts were reviewed and 
14 questionnaires were identiﬁ ed. Four instruments had both a solid development 
methodology and good psychometric properties: the CatQuest (Cataract Question-
naire), the NEI-RQL-42 (US National Eye Institute Refractive Error QoL instru-
ment-42), the NEI-VFQ-25 (US National Eye Institute Visual Function 
Questionnaire-25) and the RSVP (Refractive Status and Vision Proﬁ le). When includ-
ing the ability to assess vision-related QoL with the beneﬁ t of not wearing glasses, it 
appeared that the NEI-RQL-42 was one of the best candidates, although the beneﬁ ts 
of spectacle independence could be more deeply explored. CONCLUSIONS: Accord-
ing to this literature review, the NEI-RQL-42 could be considered as one of the best 
instruments to capture refractive vision-related QoL consequences after cataract 
surgery.
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OBJECTIVES: Estimates of the lifetime prevalence of external genital warts (EGW) 
and genital herpes in the European Union range from 0.47% to 1.52% and 0.59% 
to 1.43% respectively. The aim here is to assess, for the ﬁ rst time, the impact of the 
experience on current health related quality of life at the general population level. 
METHODS: Data are from the 2008 National Health and Wellness Survey. This is 
an internet-based survey carried out in the UK, France, Spain, Italy and Germany. 
From a total of 53,524 respondents, 521 indicated they had experienced EGW and 
520 genital herpes. Only 63 had experienced both conditions. The regression analysis 
is based on health state utilities (score 0–100) from the SF-6D. The independent 
variables included binary variables for the presence/absence of EGW and genital 
herpes, socio-demographic characteristics, health risk factors (e.g., body mass index) 
and the Charlson Comorbidity Index (CCI). RESULTS: The experience of EGW and 
genital herpes had a substantial negative impact on utility scores. The impact was 
signiﬁ cant at conventional decision levels: EGW—2.47 (95% CI: −3.58–−1.36), genital 
herpes −3.52 (95%CI: −4.63–−2.71) and EGW and genital herpes −5.00 (95%CI: 
1.76–8.25). The impact of EGW and genital herpes experience was similar to the 
negative impact of BMI for persons who were underweight, obese and morbidly obese 
and the CCI (−2.53;95%CI: −2.65–−2.41). Age, education and income all had a posi-
tive and signiﬁ cant impact on HRQoL. CONCLUSIONS: This is the ﬁ rst time the 
lifetime experience of two of the most prevalence sexually transmitted infections (STIs) 
on current HRQoL has been assessed. The results point to the continuing impact of 
this experience, with herpes having a marginally greater impact than EGWs. The 
HRQoL deﬁ cit is most apparent for those who have experienced both STIs. 
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OBJECTIVES: Evaluation of use, dose distribution, and dosing rationale of biologic 
treatments in plaque psoriasis within private practices and hospitals in Germany. 
METHODS: Fully structured Online Questionnaire using Umfragecenter® software. 
Panel participants were selected by DocCheck Medical Services using their MediAccess 
Pool. Survey was done in December 2009. 100 dermatologists (60 in private practices, 
40 in hospitals) were included in the survey. Inclusion criterion: currently treating at 
least two psoriasis patients with biologics, at least one patient on adalimumab, etan-
ercept or inﬂ iximab. RESULTS: Each surveyed dermatologist treated approximately 
100 psoriasis patients per quarter. In private practice about 10% of these patients 
were treated with a biologic, while in hospitals about 23% received biologic treatment. 
About 40% of the patients receiving a biologic suffered from psoriatic arthritis as 
well. Distribution of the different biologics used was as follows: etanercept 37%, 
adalimumab 33%, inﬂ iximab 20%, and ustekinumab 10%. Only minor differences 
in those proportions were observed between private practices and hospitals. In about 
80% of all cases, used dosing for each biologic conformed to the respective label. In 
other cases, increased dosages were observed, for example: 12% of adalimumab 
patients received 40 mg weekly, 17% of etanercept patients being treated longer than 
